Hui Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hui Li has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Yangyang Wang
Research Group of Standardization of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China
10 shared publicationsRunsheng Xie
The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
8 shared publicationsWenjia Chen
The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
6 shared publicationsLuan Zhang
The Second Clinical College of Guangzhou University of Chinese Medicine
4 shared publicationsHeba Hussein
Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Cairo, Egypt
3 shared publicationsMyeong Soo Lee
Korea Institute of Oriental Medicine
3 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by Taylor & Francis in Critical Public Health
- Vol. 36 (1)
Development and prioritization of ERIC-informed implementation strategies for Traditional Chinese Medicine guidelines: a two-phase mixed methods study
- 10 June 2026
- Published by Taylor & Francis in Critical Public Health
- Vol. 36 (1)
Open AccessDevelopment and prioritization of ERIC-informed implementation strategies for Traditional Chinese Medicine guidelines: a two-phase mixed methods study
- Open Access
- 20 January 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 42
Adapting the ADAPTE framework for Traditional Chinese Medicine clinical practice guidelines: a methodological study
Clinical practice guideline adaptation is critical for standardizing care, yet existing frameworks like the ADAPTE process lack specificity for Traditional Chinese Medicine (TCM), whose principles diverge fundamentally from western medicine. To address this gap, we modified the ADAPTE process to align with the unique characteristics of TCM. A dual-tiered working group (core team and expert panel) simulated tested the original ADAPTE process on Traditional Chinese Medicine clinical practice guidelines (TCM CPGs), identifying challenges such as incompatibility with TCM diagnostic frameworks and holistic treatment paradigms and formed the initial version of ADAPTE-TCM. 21 experts were invited to evaluate the initial version of ADAPTE-TCM and reached a high consensus, while also providing suggestions for modifications to the initial version. Ultimately, 20 steps were modified (e.g., evidence synthesis, consensus-building) and integration of TCM CPGs specific evaluation criteria and tool. The resulting ADAPTE-TCM framework provides methodological rigor for adapting TCM CPGs. This adaptation not only bridges a critical gap in TCM CPGs adaptation but also exemplifies how evidence-based methodologies can evolve to respect diverse medical traditions.
- 20 January 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 42
Open AccessAdapting the ADAPTE framework for Traditional Chinese Medicine clinical practice guidelines: a methodological study
Clinical practice guideline adaptation is critical for standardizing care, yet existing frameworks like the ADAPTE process lack specificity for Traditional Chinese Medicine (TCM), whose principles diverge fundamentally from western medicine. To address this gap, we modified the ADAPTE process to align with the unique characteristics of TCM. A dual-tiered working group (core team and expert panel) simulated tested the original ADAPTE process on Traditional Chinese Medicine clinical practice guidelines (TCM CPGs), identifying challenges such as incompatibility with TCM diagnostic frameworks and holistic treatment paradigms and formed the initial version of ADAPTE-TCM. 21 experts were invited to evaluate the initial version of ADAPTE-TCM and reached a high consensus, while also providing suggestions for modifications to the initial version. Ultimately, 20 steps were modified (e.g., evidence synthesis, consensus-building) and integration of TCM CPGs specific evaluation criteria and tool. The resulting ADAPTE-TCM framework provides methodological rigor for adapting TCM CPGs. This adaptation not only bridges a critical gap in TCM CPGs adaptation but also exemplifies how evidence-based methodologies can evolve to respect diverse medical traditions.
- Open Access
- 28 July 2025
- Published by SAGE Publications in Journal of Mixed Methods Research
- Vol. 20 (2) , 160-183
Mixed Methods Research in the Field of Clinical Practice Guidelines: The Case of Developing a Methodological Model for Good Practice Recommendation
Mixed methods research provides a valuable opportunity to deepen our understanding of phenomena. However, practical guidance on using the method to develop methodological models in clinical practice guidelines (CPGs) field is limited. This article illustrates the use of exploratory sequential mixed methods design to develop a methodological model to standardize the formation of good practice recommendation (GPR) within CPGs in the context of weak evidence or no evidence. It demonstrates how qualitative and quantitative data can be systematically integrated throughout the model construction and validation. The GPR methodological model includes three main themes: connotation , procedure and methods , and reporting guideline . It assists CPGs developers in GPR formulation, aligns researchers’ methodological understanding of GPR, and informs future GPR methodological development.
- 28 July 2025
- Published by SAGE Publications in Journal of Mixed Methods Research
- Vol. 20 (2) , 160-183
Open AccessMixed Methods Research in the Field of Clinical Practice Guidelines: The Case of Developing a Methodological Model for Good Practice Recommendation
Mixed methods research provides a valuable opportunity to deepen our understanding of phenomena. However, practical guidance on using the method to develop methodological models in clinical practice guidelines (CPGs) field is limited. This article illustrates the use of exploratory sequential mixed methods design to develop a methodological model to standardize the formation of good practice recommendation (GPR) within CPGs in the context of weak evidence or no evidence. It demonstrates how qualitative and quantitative data can be systematically integrated throughout the model construction and validation. The GPR methodological model includes three main themes: connotation , procedure and methods , and reporting guideline . It assists CPGs developers in GPR formulation, aligns researchers’ methodological understanding of GPR, and informs future GPR methodological development.
- Open Access
- 18 March 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1590371
Corrigendum: Development and validation a methodology model for traditional Chinese medicine good practice recommendation: an exploratory sequential mixed methods study
Corrigendum on: Li S, Zhang L, Wang Y, Xie R, Chen W, Lee MS, Amer YS, Sharifan A, Hussein H and Li H (2025) Development and validation a methodology model for traditional Chinese medicine good practice recommendation: an exploratory sequential mixed methods study. Front. Pharmacol. 16:1501634. doi: 10.3389/fphar.2025.1501634 In the published article, there was an error in affiliations 1, 2, and 10. Instead of " 1 Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China," " 2 The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China" and " 10 Oral Medicine, Oral Diagnosis, and Periodontology Department, Cairo University, Giza, Giza,
- 18 March 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1590371
Open AccessCorrigendum: Development and validation a methodology model for traditional Chinese medicine good practice recommendation: an exploratory sequential mixed methods study
Corrigendum on: Li S, Zhang L, Wang Y, Xie R, Chen W, Lee MS, Amer YS, Sharifan A, Hussein H and Li H (2025) Development and validation a methodology model for traditional Chinese medicine good practice recommendation: an exploratory sequential mixed methods study. Front. Pharmacol. 16:1501634. doi: 10.3389/fphar.2025.1501634 In the published article, there was an error in affiliations 1, 2, and 10. Instead of " 1 Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China," " 2 The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China" and " 10 Oral Medicine, Oral Diagnosis, and Periodontology Department, Cairo University, Giza, Giza,
- Open Access
- 31 January 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1501634
Development and validation a methodology model for traditional Chinese medicine good practice recommendation: an exploratory sequential mixed methods study
Background: To develop a rational and standardized traditional Chinese medicine (TCM) good practice recommendation (GPR) methodology model that guides the formulation of recommendations grounded in clinical experience.Methods: We adopted an exploratory sequential mixed-method to develop a methodology model by coding systematically collected literature on methodology and TCM guidelines related to TCM GPR using a best-fit framework synthesis. Then based on real-world data (published TCM guidelines), saturation tests, structural rationality validation, and discriminability tests were conducted to validate methodology model.Results: A total of 35 methodological literature and 190 TCM guidelines were included. A TCM GPR methodology model was developed, including 3 themes, 10 sub-themes, and the relationships between themes and subthemes. The information of TCM GPR methodology model achieved data saturation. The fit indices were within the acceptable range, and were able to distinguish the overall differences between guidelines from different literature sources, development organizations, guideline types, discipline categories, and funding categories.Conclusion: The study developed a TCM GPR methodology model which describes the definition of a TCM GPR, how to formulate it, and how to report it. The methodology modeldemonstrates good fit, discriminability, and data saturation. It can standardize the specific formulation of TCM GPRs, facilitate the scientific and rational formation of TCM GPRs, and provide theoretical and methodological guidance for the formation of TCM GPRs.
- 31 January 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1501634
Open AccessDevelopment and validation a methodology model for traditional Chinese medicine good practice recommendation: an exploratory sequential mixed methods study
Background: To develop a rational and standardized traditional Chinese medicine (TCM) good practice recommendation (GPR) methodology model that guides the formulation of recommendations grounded in clinical experience.Methods: We adopted an exploratory sequential mixed-method to develop a methodology model by coding systematically collected literature on methodology and TCM guidelines related to TCM GPR using a best-fit framework synthesis. Then based on real-world data (published TCM guidelines), saturation tests, structural rationality validation, and discriminability tests were conducted to validate methodology model.Results: A total of 35 methodological literature and 190 TCM guidelines were included. A TCM GPR methodology model was developed, including 3 themes, 10 sub-themes, and the relationships between themes and subthemes. The information of TCM GPR methodology model achieved data saturation. The fit indices were within the acceptable range, and were able to distinguish the overall differences between guidelines from different literature sources, development organizations, guideline types, discipline categories, and funding categories.Conclusion: The study developed a TCM GPR methodology model which describes the definition of a TCM GPR, how to formulate it, and how to report it. The methodology modeldemonstrates good fit, discriminability, and data saturation. It can standardize the specific formulation of TCM GPRs, facilitate the scientific and rational formation of TCM GPRs, and provide theoretical and methodological guidance for the formation of TCM GPRs.
- Open Access
- 19 November 2024
- Published by Elsevier in Technological Forecasting and Social Change
- Vol. 210
Innovation in internet plus pharmaceutical services model in the health 4.0 context: Evidence from a repeated cross-sectional study
- 19 November 2024
- Published by Elsevier in Technological Forecasting and Social Change
- Vol. 210
Open AccessInnovation in internet plus pharmaceutical services model in the health 4.0 context: Evidence from a repeated cross-sectional study
- Open Access
Causal links between mitophagy and Alzheimer’s disease: a Mendelian randomization study
Background: Emerging evidence highlights the dysregulation of mitophagy, the process of clearing damaged mitochondria, as a potential contributor to Alzheimer’s disease (AD) pathology. However, the precise mechanisms linking mitophagy to AD remain poorly understood. This study utilized summary-data-based Mendelian Randomization (SMR) combined with multi-omics data to explore the causal relationships between them, and to uncover potential epigenetic mechanisms of gene regulation. Methods: Mitophagy-related genes were identified through the integration of three databases, and transcriptomic data of AD patients were obtained from the Gene Expression Omnibus (GEO) database. A meta-analysis was conducted to recognize differentially expressed genes (DEGs) associated with mitophagy in AD. Through SMR tools, genome-wide association study (GWAS) summary data of AD from the GWAS Catalog (n=487,511) were separately integrated with expression quantitative trait loci (eQTLs) and DNA methylation quantitative trait loci (mQTLs) from blood and brain tissues to identify potentially causal genes and methylation sites. The findings from primary analysis were validated with data from the UK Biobank (n=301,478). Results: In total, 111 mitophagy-related genes were found to be differentially expressed in AD. The three-step SMR analysis identified two genes, PARL and BCL2L1, from blood tissues and three genes, ATG13, TOMM22, and SPATA33, from brain tissues as causal candidate genes associated with AD. The analysis pinpointed the possible epigenetic mechanisms, where specific methylation sites regulate the expression of these genes, potentially contributing to their association with AD. All findings were successfully replicated in UK Biobank cohorts. Conclusions: The study emphasized the putatively causal relationships of mitophagy-related gene with AD. These underlying pathogenic mechanisms could pave the way for new approaches in early detection and therapeutic intervention for AD.
Open AccessCausal links between mitophagy and Alzheimer’s disease: a Mendelian randomization study
Background: Emerging evidence highlights the dysregulation of mitophagy, the process of clearing damaged mitochondria, as a potential contributor to Alzheimer’s disease (AD) pathology. However, the precise mechanisms linking mitophagy to AD remain poorly understood. This study utilized summary-data-based Mendelian Randomization (SMR) combined with multi-omics data to explore the causal relationships between them, and to uncover potential epigenetic mechanisms of gene regulation. Methods: Mitophagy-related genes were identified through the integration of three databases, and transcriptomic data of AD patients were obtained from the Gene Expression Omnibus (GEO) database. A meta-analysis was conducted to recognize differentially expressed genes (DEGs) associated with mitophagy in AD. Through SMR tools, genome-wide association study (GWAS) summary data of AD from the GWAS Catalog (n=487,511) were separately integrated with expression quantitative trait loci (eQTLs) and DNA methylation quantitative trait loci (mQTLs) from blood and brain tissues to identify potentially causal genes and methylation sites. The findings from primary analysis were validated with data from the UK Biobank (n=301,478). Results: In total, 111 mitophagy-related genes were found to be differentially expressed in AD. The three-step SMR analysis identified two genes, PARL and BCL2L1, from blood tissues and three genes, ATG13, TOMM22, and SPATA33, from brain tissues as causal candidate genes associated with AD. The analysis pinpointed the possible epigenetic mechanisms, where specific methylation sites regulate the expression of these genes, potentially contributing to their association with AD. All findings were successfully replicated in UK Biobank cohorts. Conclusions: The study emphasized the putatively causal relationships of mitophagy-related gene with AD. These underlying pathogenic mechanisms could pave the way for new approaches in early detection and therapeutic intervention for AD.
- Open Access
- 30 May 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2357235
Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis
Tension-type headache is the most common type of primary headache and results in a huge socioeconomic burden. This network meta-analysis (NMA) aimed to compare the efficacy and safety of simple analgesics for the treatment of episodic tension-type headache (ETTH) in adults. We searched the Cochrane Library, PubMed, Web of Science, Embase, Chinese BioMedical Literature database and International Clinical Trials Registry Platform databases for eligible randomized clinical trials reporting the efficacy and/or safety of simple analgesics. A Bayesian NMA was performed to compare relative efficacy and safety. The surface under the cumulative ranking curve (SUCRA) was calculated to rank interventions. PROSPERO registration number: CRD42018090554. We highlighted six studies including 3507 patients. For the 2 h pain-free rate, the SUCRA ranking was ibuprofen > diclofenac-K > ketoprofen > acetaminophen > naproxen > placebo. All drugs except naproxen reported a higher 2 h pain-free rate than placebo, with a risk ratio (RR) of 2.86 (95% credible interval, CrI: 1.62–5.42) for ibuprofen and 2.61 (1.53–4.88) for diclofenac-K. For adverse events rate, the SUCRA ranking was: metamizol > diclofenac-K > ibuprofen > lumiracoxib > placebo > aspirin > acetaminophen > naproxen > ketoprofen. The adverse event rates of all analgesics were no higher than those of placebo, except for ketoprofen. Moreover, all drugs were superior to placebo in the global assessment of efficacy. In particular, the RR of lumiracoxib was 2.47 (1.57–4.57). Global heterogeneity I2 between the studies was low. Simple analgesics are considered more effective and safe as a placebo for ETTH in adults. Our results suggest that ibuprofen and diclofenac-K may be the two best treatment options for patients with ETTH from a comprehensive point of view (both high-quality evidence).
- 30 May 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2357235
Open AccessEfficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis
Tension-type headache is the most common type of primary headache and results in a huge socioeconomic burden. This network meta-analysis (NMA) aimed to compare the efficacy and safety of simple analgesics for the treatment of episodic tension-type headache (ETTH) in adults. We searched the Cochrane Library, PubMed, Web of Science, Embase, Chinese BioMedical Literature database and International Clinical Trials Registry Platform databases for eligible randomized clinical trials reporting the efficacy and/or safety of simple analgesics. A Bayesian NMA was performed to compare relative efficacy and safety. The surface under the cumulative ranking curve (SUCRA) was calculated to rank interventions. PROSPERO registration number: CRD42018090554. We highlighted six studies including 3507 patients. For the 2 h pain-free rate, the SUCRA ranking was ibuprofen > diclofenac-K > ketoprofen > acetaminophen > naproxen > placebo. All drugs except naproxen reported a higher 2 h pain-free rate than placebo, with a risk ratio (RR) of 2.86 (95% credible interval, CrI: 1.62–5.42) for ibuprofen and 2.61 (1.53–4.88) for diclofenac-K. For adverse events rate, the SUCRA ranking was: metamizol > diclofenac-K > ibuprofen > lumiracoxib > placebo > aspirin > acetaminophen > naproxen > ketoprofen. The adverse event rates of all analgesics were no higher than those of placebo, except for ketoprofen. Moreover, all drugs were superior to placebo in the global assessment of efficacy. In particular, the RR of lumiracoxib was 2.47 (1.57–4.57). Global heterogeneity I2 between the studies was low. Simple analgesics are considered more effective and safe as a placebo for ETTH in adults. Our results suggest that ibuprofen and diclofenac-K may be the two best treatment options for patients with ETTH from a comprehensive point of view (both high-quality evidence).
- Open Access
- 22 January 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1276631
Osteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis
Objective: The aims of this study were to evaluate the quality of osteoporosis guidelines on traditional Chinese medicine (TCM) drug therapies and to analyze the specific recommendations of these guidelines.Methods: We systematically collected guidelines, evaluated the quality of the guidelines using the Appraisal of Guidelines Research and Evaluation (AGREE) II tool, and summarized the recommendations of TCM drug therapies using the Patient-Intervention-Comparator-Outcome (PICO) model as the analysis framework.Results and conclusions: A total of 20 guidelines were included. Overall quality evaluation results revealed that four guidelines were at level A, four at level B, and 12 at level C, whose quality needed to be improved in the domains of “stakeholder involvement”, “rigor of development”, “applicability” and “editorial independence”. Stratified analysis suggested that the post-2020 guidelines were significantly better than those published before 2020 in the domains of “scope and purpose”, “stakeholder involvement” and “editorial independence”. Guidelines with evidence systems were significantly better than those without evidence systems in terms of “stakeholder involvement”, “rigor of development”, “clarity of presentation” and “applicability”. The guidelines recommended TCM drug therapies for patients with osteopenia, osteoporosis and osteoporotic fracture. Recommended TCM drugs were mainly Chinese patent medicine alone or combined with Western medicine, with the outcome mainly focused on improving bone mineral density (BMD).
- 22 January 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1276631
Open AccessOsteoporosis guidelines on TCM drug therapies: a systematic quality evaluation and content analysis
Objective: The aims of this study were to evaluate the quality of osteoporosis guidelines on traditional Chinese medicine (TCM) drug therapies and to analyze the specific recommendations of these guidelines.Methods: We systematically collected guidelines, evaluated the quality of the guidelines using the Appraisal of Guidelines Research and Evaluation (AGREE) II tool, and summarized the recommendations of TCM drug therapies using the Patient-Intervention-Comparator-Outcome (PICO) model as the analysis framework.Results and conclusions: A total of 20 guidelines were included. Overall quality evaluation results revealed that four guidelines were at level A, four at level B, and 12 at level C, whose quality needed to be improved in the domains of “stakeholder involvement”, “rigor of development”, “applicability” and “editorial independence”. Stratified analysis suggested that the post-2020 guidelines were significantly better than those published before 2020 in the domains of “scope and purpose”, “stakeholder involvement” and “editorial independence”. Guidelines with evidence systems were significantly better than those without evidence systems in terms of “stakeholder involvement”, “rigor of development”, “clarity of presentation” and “applicability”. The guidelines recommended TCM drug therapies for patients with osteopenia, osteoporosis and osteoporotic fracture. Recommended TCM drugs were mainly Chinese patent medicine alone or combined with Western medicine, with the outcome mainly focused on improving bone mineral density (BMD).
- Open Access
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1057920
AGREE II for TCM: Tailored to evaluate methodological quality of TCM clinical practice guidelines
Background: The Appraisal of Guidelines Research and Evaluation (AGREE) II instrument has been widely used in the methodological quality assessment of clinical practice guidelines (CPG). Chinese medicine CPGs have unique characteristics which distinguish them from those of Western medicine, e.g. syndrome differentiation, on which treatments are based. As such, certain domains and items in AGREE II are unsuitable for assessing TCM CPGs. Therefore, it is necessary to adjust and supplement the description and rating section of some items of the AGREE Ⅱinstrument.Purpose: To adjust and expand AGREE II according to characteristics of TCM clinical practice guidelines.Methods: A research working group was established, consisting of a core working group and an expert consensus group, before a systematic literature search performed to screen for TCM guidelines. Two researchers evaluated the quality of the included guidelines using AGREE Ⅱ and later proposed adjustments to some items of AGREE Ⅱ and supplementary comments, which were applicable to TCM CPGs, and drafted an initial version of AGREE Ⅱ for TCM. Suggestions from literature on development and evaluation of TCM CPGs were solicited and integrated into the revised version, which 16 experts were then invited to advise on. When the experts reached a consensus, their comments to the draft were adopted by the core group into the final version.Results: After evaluating the included TCM guidelines, the two researchers offered adjustments and supplementary comments for AGREE Ⅱ Items 1, 7, 10, 11, 12, 15, and 18, and drafted an initial version of AGREE Ⅱ for TCM. Combining suggestions from the literature on development and quality evaluation of TCM clinical guidelines, the core working group modified AGREE Ⅱ items 2, 4, 5, 8, 9, 13, 20, and 21, then proposed the revised version of AGREE Ⅱ for TCM, on which was advised by a group of experts, before consensus on improvements was reached. The results of the first round of expert surveys showed strong agreement, and experts’ opinions were adopted into the final version of AGREE Ⅱ for TCM.Conclusion: Based on the characteristics of the TCM CPGs, we adjustment and expansion were made to create AGREE II for TCM. This version is suitable for the assessment of methodological quality of TCM CPGs, capable of providing content support for the standardization of procedures and methods of formulating TCM CPGs.
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1057920
Open AccessAGREE II for TCM: Tailored to evaluate methodological quality of TCM clinical practice guidelines
Background: The Appraisal of Guidelines Research and Evaluation (AGREE) II instrument has been widely used in the methodological quality assessment of clinical practice guidelines (CPG). Chinese medicine CPGs have unique characteristics which distinguish them from those of Western medicine, e.g. syndrome differentiation, on which treatments are based. As such, certain domains and items in AGREE II are unsuitable for assessing TCM CPGs. Therefore, it is necessary to adjust and supplement the description and rating section of some items of the AGREE Ⅱinstrument.Purpose: To adjust and expand AGREE II according to characteristics of TCM clinical practice guidelines.Methods: A research working group was established, consisting of a core working group and an expert consensus group, before a systematic literature search performed to screen for TCM guidelines. Two researchers evaluated the quality of the included guidelines using AGREE Ⅱ and later proposed adjustments to some items of AGREE Ⅱ and supplementary comments, which were applicable to TCM CPGs, and drafted an initial version of AGREE Ⅱ for TCM. Suggestions from literature on development and evaluation of TCM CPGs were solicited and integrated into the revised version, which 16 experts were then invited to advise on. When the experts reached a consensus, their comments to the draft were adopted by the core group into the final version.Results: After evaluating the included TCM guidelines, the two researchers offered adjustments and supplementary comments for AGREE Ⅱ Items 1, 7, 10, 11, 12, 15, and 18, and drafted an initial version of AGREE Ⅱ for TCM. Combining suggestions from the literature on development and quality evaluation of TCM clinical guidelines, the core working group modified AGREE Ⅱ items 2, 4, 5, 8, 9, 13, 20, and 21, then proposed the revised version of AGREE Ⅱ for TCM, on which was advised by a group of experts, before consensus on improvements was reached. The results of the first round of expert surveys showed strong agreement, and experts’ opinions were adopted into the final version of AGREE Ⅱ for TCM.Conclusion: Based on the characteristics of the TCM CPGs, we adjustment and expansion were made to create AGREE II for TCM. This version is suitable for the assessment of methodological quality of TCM CPGs, capable of providing content support for the standardization of procedures and methods of formulating TCM CPGs.